Literature DB >> 28299663

RUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML.

R Katherine Hyde1, Paul Liu2, Alan D Friedman3.   

Abstract

Mutations in RUNX1 and CBFB have long been recognized as important in hematological malignancies. Point mutations and deletions of RUNX1 are frequently found in myelodysplastic syndrome, myeloproliferative disease, and acute myeloid leukemia. Germline mutations in RUNX1 are associated with familial platelet disorder with predisposition to AML. In addition, as will be discussed in other chapters, both RUNX1 and CBFB are involved in recurrent chromosomal rearrangements in leukemia. More recently, roles for the non-mutated RUNX1 and CBFB genes have been identified in multiple leukemia subtypes. This chapter will discuss the roles of RUNX1 and CBFB, both in diseases caused by their mutations or deletions, as well as in the context of chromosomal rearrangements.

Entities:  

Keywords:  AML; CBFB; Inv(16); MDS; MLL; MPD; RUNX1; t(8;21)

Mesh:

Substances:

Year:  2017        PMID: 28299663     DOI: 10.1007/978-981-10-3233-2_17

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  5 in total

1.  HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.

Authors:  Lisa E Richter; Yiqian Wang; Michelle E Becker; Rachel A Coburn; Jacob T Williams; Catalina Amador; R Katherine Hyde
Journal:  Mol Cancer Res       Date:  2019-02-27       Impact factor: 5.852

Review 2.  Targeting transcription cycles in cancer.

Authors:  Stephin J Vervoort; Jennifer R Devlin; Nicholas Kwiatkowski; Mingxing Teng; Nathanael S Gray; Ricky W Johnstone
Journal:  Nat Rev Cancer       Date:  2021-10-21       Impact factor: 60.716

3.  Use of polymeric CXCR4 inhibitors as siRNA delivery vehicles for the treatment of acute myeloid leukemia.

Authors:  Yiqian Wang; Ying Xie; Jacob Williams; Yu Hang; Lisa Richter; Michelle Becker; Catalina Amador; David Oupický; R Katherine Hyde
Journal:  Cancer Gene Ther       Date:  2019-04-26       Impact factor: 5.987

4.  RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.

Authors:  Christopher P Mill; Warren Fiskus; Courtney D DiNardo; Yimin Qian; Kanak Raina; Kimal Rajapakshe; Dimuthu Perera; Cristian Coarfa; Tapan M Kadia; Joseph D Khoury; Dyana T Saenz; David N Saenz; Anuradha Illendula; Koichi Takahashi; Steven M Kornblau; Michael R Green; Andrew P Futreal; John H Bushweller; Craig M Crews; Kapil N Bhalla
Journal:  Blood       Date:  2019-04-25       Impact factor: 25.476

Review 5.  Preleukemia and Leukemia-Initiating Cell Activity in inv(16) Acute Myeloid Leukemia.

Authors:  John Anto Pulikkan; Lucio Hernán Castilla
Journal:  Front Oncol       Date:  2018-04-26       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.